Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors | Zendy

Emiel Leegwater | Zendy; Anne S. Strik | Zendy; Erik B. Wilms | Zendy; Liesbeth Bosma | Zendy; David M. Burger | Zendy; Thomas H. Ottens | Zendy; Cees van Nieuwkoop | Zendy

Open Access

Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors

Author(s) -

Emiel Leegwater,

Anne S. Strik,

Erik B. Wilms,

Liesbeth Bosma,

David M. Burger,

Thomas H. Ottens,

Cees van Nieuwkoop

Publication year - 2020

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciaa883

Subject(s) - glycoprotein , medicine , covid-19 , liver injury , p glycoprotein , coronavirus , disease , drug , medical prescription , pharmacology , virology , infectious disease (medical specialty) , chemistry , biology , drug resistance , outbreak , biochemistry , multiple drug resistance , microbiology and biotechnology

We report a case of a man with COVID-19 who developed acute hepatotoxicity related to remdesivir with probable interaction of P-glycoprotein (P-gp) inhibitors. Until further details on this interaction become available, we recommend physicians to be cautious with the prescription of P-gp inhibitors in patients receiving remdesivir therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research